GlassScriptPhysician profile
Yasser Moussa Aleech
NPI 1871698639
$2,481.88
in general payments reported to CMS, 2019-2025
29 companies · $793 in 2025
The $793 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.90 · 2020: $137 · 2021: $104 · 2022: $248 · 2023: $479 · 2024: $663 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,918 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,917.74 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $334.14 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $301.65 | 2020-2025 | Breztri, Fasenra, Tezspire |
| Inspire Medical Systems, INC. | $258.65 | 2024-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.22 | 2021-2025 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Insmed, INC. | $180.66 | 2021-2025 | Brinsupri, Arikayce |
| Grifols USA, LLC | $166.76 | 2022-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $124.33 | 2021-2024 | Yupelri |
| Daiichi Sankyo INC. | $122.03 | 2020 | |
| Harmony Biosciences LLC | $108.50 | 2021-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $81.58 | 2024-2025 | Dupixent |
| United Therapeutics Corporation | $67.37 | 2024-2025 | Tyvaso, Tyvaso |
| E.R. Squibb & Sons, L.L.C. | $53.31 | 2022-2023 | Eliquis |
| Genzyme Corporation | $49.72 | 2022-2025 | |
| Genentech USA, INC. | $45.74 | 2023-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $45.53 | 2024-2025 | Glassia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $44.41 | 2023-2024 | Smartvest |
| Axsome Therapeutics, INC. | $34.30 | 2023 | Sunosi |
| Viatris Specialty LLC | $34.26 | 2025 | Yupelri |
| Zoll Respicardia, INC. | $31.26 | 2024 | Remede System |
| Baxter Healthcare | $29.25 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Inogen, INC. | $25.67 | 2024 | |
| Verona Pharma, INC. | $22.80 | 2025 | Ohtuvayre |
| Resmed Corp | $21.86 | 2025 | |
| Merck Sharp & Dohme LLC | $20.97 | 2023 | |
| Pfizer INC. | $18.22 | 2025 | |
| 3b Medical, INC. | $15.43 | 2025 | Luna |
| Mallinckrodt Enterprises LLC | $14.98 | 2019 | |
| Sandoz INC. | $14.66 | 2024 | Treprostinil |
| Philips North America LLC | $12.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasser Moussa Aleech listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.